ESMO: Lynparza, Zejula Continue Rivalry With Long-Term Ovarian Maintenance Data
Executive Summary
AstraZeneca/Merck’s Lynparza showed an OS benefit in first-line maintenance of ovarian cancer, but while data for Zejula were less mature, the GSK drug targets a broader population.